Clinical Report: Itch Assessment Practices in UK Atopic Dermatitis Care

Overview

Chronic itch is the most burdensome symptom in atopic dermatitis (AD) and significantly impacts patient quality of life. Despite recognition of itch as a key treatment goal by UK dermatologists, fewer than one-third consistently use validated tools to assess itch in routine practice.

Background

Atopic dermatitis is a common inflammatory skin condition characterized by chronic itch affecting up to 100% of patients. Itch severity often does not correlate with skin lesion severity but strongly influences sleep, mental health, and quality of life. Recent treat-to-target guidelines emphasize itch reduction as a primary goal, recommending validated patient-reported measures such as the peak pruritus numerical rating scale (PP-NRS). The pathophysiology of AD itch involves complex neuroimmune interactions distinct from histaminergic pathways, complicating management. Effective itch assessment is critical to guide treatment and improve patient outcomes.

Data Highlights

Key Findings

• Chronic itch is the predominant and most distressing symptom for patients with AD, reported by nearly 79% of UK dermatologists as the most bothersome.
• Itch is recognized as the primary treatment target by over half of dermatologists (56.35%).
• Less than 30% of dermatologists routinely use validated itch assessment tools such as the PP-NRS or visual analogue scale (VAS).
• Itch severity often does not correlate with skin lesion severity, underscoring the need for direct itch measurement.
• Validated patient-reported outcome measures are practical, sensitive, and recommended to standardize itch assessment in clinical workflows.
• Uncontrolled itch contributes to sleep disturbance, mental health impairment, and overall disease burden in AD patients.

Clinical Implications

Clinicians should prioritize routine, standardized assessment of itch using validated tools like the PP-NRS or VAS to better capture patient symptom burden and guide treatment decisions. Embedding these measures into clinical practice can improve monitoring of disease activity and treatment response, ultimately enhancing patient quality of life. Recognizing itch as a distinct and critical domain in AD management supports more patient-centered care.

Conclusion

There is a clear gap between the recognized importance of itch in AD and its consistent measurement in UK dermatology practice. Implementing simple, validated itch assessment tools can bridge this gap and improve disease management outcomes.

References

1. Augustin et al. 2014 -- Importance of itch in AD patients
2. Chovatiya et al. 2021 -- AD phenotypes based on itch and lesion severity
3. AHEAD international consensus 2023 -- Treat-to-target in AD
4. Yosipovitch et al. 2019 -- Relationship between itch and pain in AD